Monte Rosa Therapeutics, Inc. (GLUE) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$22.80M | -154.3% |
| 2024 | $42.00M | +195.9% |
| 2023 | -$43.80M | +52.6% |
| 2022 | -$92.47M | -55.8% |
| 2021 | -$59.36M | -157.5% |
| 2020 | -$23.05M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$22.80M | -154.3% |
| 2024 | $42.00M | +195.9% |
| 2023 | -$43.80M | +52.6% |
| 2022 | -$92.47M | -55.8% |
| 2021 | -$59.36M | -157.5% |
| 2020 | -$23.05M | — |